Non-bracket oblique traction-hoisting construction strategy for cable-truss structures.

This study describes the non-bracket oblique traction-hoisting construction strategy for cable-truss structures, which is to assemble the upper and lower radial cables, hoop cables, sling cables, and compression rods without stress at a low altitude, then hoist the cable-strut system to a high altitude by oblique traction of the upper radial cables through the jack fixed on the upper radial anchorage nodes, and finally actively tension the lower radial cables to achieve the designed shape and prestress level of the entire structure. This strategy assembles at a low altitude, requires simple operations, results in high tensioning efficiency, and does not require brackets, which could guarantee both quality and quantity in terms of completing the construction of cable-truss structures. The semilune-shaped canopy of Yueqing Stadium is constructed using this strategy. The construction simulation and disturbance stability analyses of the structure in the traction-hoisting state and prestress tensioning state are conducted using a nonlinear dynamic finite element method. In the traction-hoisting stage, the deformation changes sharply, and the hoop cables and upper radial cables make up the primary bearing substructure, while the lower radial cables are in a suspended hanging state. In the forming process, the forces of the radial and hoop cables increase gradually, and the structure finally reaches the designed state. For cable-trusses with crossed upper and lower radial cables, the additional stabilizing tooling ropes should be tied at the top of the middle rods to ensure geometric stability because they are susceptible to excessive out-of-plane displacement or even overturning, which is the least desirable at the beginning of traction hoisting.

Benzothiazole Amides as TRPC3/6 Inhibitors for Gastric Cancer Treatment.

Transient receptor potential canonical channel 6 (TRPC6) has been implicated in many kinds of malignant tumors, but very few potent TRPC6 antagonists are available. In this study, a benzothiazole amide derivative 1a was discovered as a TRPC6 activator in a cell-based high-throughput screening. A series of benzothiazole amide derivatives were designed and synthesized. The docking analyses indicated that the conformations of the compounds bound to TRPC6 determined the agonistic or antagonistic activity of the compounds against TRPC6, and compound 1s with the tetrahydronaphthalene group in R1 position fit well into the binding pocket of the antagonist-bound conformation of TRPC6. Compound 1s showed an inhibitory potency order of TRPC3 (IC50 3.3 ± 0.13 µM) ≈ C6 (IC50 4.2 ± 0.1 µM) > C7 with good anti-gastric cancer activity in a micromolecular range against AGS and MKN-45, respectively. In addition, 1s inhibited the invasion and migration of MKN-45 cells in vitro.

Pyrazolo[1,5-a]pyrimidine TRPC6 antagonists for the treatment of gastric cancer.

Transient receptor potential canonical 6 (TRPC6) proteins form receptor-operated Ca2+-permeable channels, which have been thought to bring benefit to the treatment of diseases, including cancer. However, selective antagonists for TRPC channels are rare and none of them has been tested against gastric cancer. Compound 14a and analogs were synthesized by chemical elaboration of previously reported TRPC3/6/7 agonist 4o. 14a had very weak agonist activity at TRPC6 expressed in HEK293 cells but exhibited strong inhibition on both 4o-mediated and receptor-operated activation of TRPC6 with an IC50 of about 1 µM. When applied to the culture media, 14a suppressed proliferation of AGS and MKN45 cells with IC50 values of 17.1 ±â€¯0.3 and 18.5 ±â€¯1.0 µM, respectively, and inhibited tube formation and migration of cultured human endothelial cells. This anti-tumor effect on gastric cancer was further verified in xenograft models using nude mice. This study has found a new tool compound which shows excellent therapeutic potential against human gastric cancer most likely through targeting TRPC6 channels.

Novel bright-emission small-molecule NIR-II fluorophores for in vivo tumor imaging and image-guided surgery.

Though high brightness and biocompatible small NIR-II dyes are highly desirable in clinical or translational cancer research, their fluorescent cores are relatively limited and their synthetic processes are somewhat complicated. Herein, we have explored the design and synthesis of novel NIR-II fluorescent materials (H1) without tedious chromatographic isolation with improved fluorescence performance (QY ≈ 2%) by introducing 2-amino 9,9-dialkyl-substituted fluorene as a donor into the backbone. Several types of water-soluble and biocompatible NIR-II probes: SXH, SDH, and H1 NPs were constructed via different chemical strategies based on H1, and then their potential to be used in in vivo tumor imaging and image-guided surgery in the NIR-II region was explored. High levels of uptake were obtained for both passive and active tumor targeting probes SXH and SDH. Furthermore, high resolution imaging of blood vessels on tumors and the whole body of living mice using H1 NPs for the first time has demonstrated precise NIR-II image-guided sentinel lymph node (SLN) surgery.

Pyrazolopyrimidines as Potent Stimulators for Transient Receptor Potential Canonical 3/6/7 Channels.

Transient receptor potential canonical 3/6/7 (TRPC3/6/7) are highly homologous receptor-operated nonselective cation channels. Despite their physiological significance, very few selective and potent agonists are available for functional examination of these channels. Using a cell-based high throughput screening approach, a lead compound with the pyrazolopyrimidine skeleton was identified as a TRPC6 agonist. Synthetic schemes for the lead and its analogues were established, and structural-activity relationship studies were carried out. A series of potent and direct agonists of TRPC3/6/7 channels were identified, and among them, 4m-4p have a potency order of TRPC3 > C7 > C6, with 4n being the most potent with an EC50 of <20 nM on TRPC3. Importantly, these compounds exhibited no stimulatory activity on related TRP channels. The potent and selective compounds described here should be suitable for evaluation of the roles of TRPC channels in the physiology and pathogenesis of diseases, including glomerulosclerosis and cancer.